Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.53 |
| ▸ | GIPR | P48546 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648042 | 1.00 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2648150 | 1.00 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647843 | 0.95 | TRPV1 (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647844 | 0.95 | TRPV1 (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647920 | 0.94 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647916 | 0.94 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2649410 | 0.92 | MAPK14 (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2649415 | 0.92 | MAPK14 (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2665161 | 0.91 | GCGR (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2655666 | 0.89 | GCGR (0.49) | GCGRGIPRCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885GIPR 3/4885CYP3A4 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.